Abstract

It is widely known that many of cats die from kidney disease. Even if cats are fed a low-sodium diet, kidney function will always decline with age. Until now, the cause of kidney disease in cats has been completely unknown.

However, Dr. Toru Miyazaki, the author of this book, discovered the blood protein called "AIM (Apoptosis Inhibitor of Macrophage)" and elucidated that cats suffer from kidney disease because AIM doesn't function properly.

Since AIM's malfunction leads to kidney disease, it naturally follows that supplementing AIM should prevent its onset. If this AIM medicine for cats have been developed, cats may live to be even 30 years old, twice the current average lifespan.

This is tremendous good news for cat lovers. Furthermore, AIM is expected to be effective not only for felines but also for humans, and to be used not only for kidney disease but also for Alzheimer's disease, autoimmune disease, and other diseases that have been said to be "incurable".


TABLE OF CONTENTS (tentative translation)

Introduction A Physician Take on the Challenge of Developing a Cat Drug
Prologue Resurrection from "One Week to Live"
Chapter 1 From Clinical to Basic Medicine
Chapter 2 My Training Period
Chapter 3 Encounter with the Mysterious Protein "AIM"
Chapter 4 "Incurable" Diseases and AIM
Chapter 5 "Garbage Cleaning" by AIM and Kidney Disease
Chapter 6 Feline Kidney Disease and AIM
Chapter 7 Administration of AIM to Cats with Kidney Disease
Chapter 8 Development of a Feline Drug
Chapter 9 Toward Clinical Trials
Chapter 10 COVID-19 and AIM

Author’s Information

Toru Miyazaki
President and Director of the Institute for AIM Medicine (IAM)

Graduated from the University of Tokyo School of Medicine in 1986. Joined the Third Internal Medicine Department of the University of Tokyo Hospital. After completing studies at Kumamoto University Graduate School, worked as a researcher at the Louis Pasteur University of Strasbourg/IGBMC (France) from 1992, Principal Researcher at the Basel Institute for Immunology (Switzerland) from 1995, Associate Professor at Center for Immunology at the University of Texas Southwestern Medical Center at Dallas (USA) from 2000, and served as a professor at the Graduate School of Medicine, University of Tokyo, from 2006 to 2022.
Since April 2022, he has been the President and Director of the Institute for AIM Medicine (IAM). In 1999, he discovered AIM and subsequently advanced his research, promoting AIM drug development for various diseases including kidney disease. During this time, he discovered that AIM is congenitally dysfunctional in cats, leading to the development of AIM-based veterinary medicine targeting kidney disease in cats.